Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …